PBCAR19B

N/A

Report date: 2023/06/27 20:00:33

Base Information

Drug NamePBCAR19B

Drug Alias NamePBCAR-19B

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapyCell and gene therapy > Gene therapy

Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsAnti-CD19

TargetsB-lymphocyte antigen CD19

Therapy Area/IndicationsHematologic NeoplasmsNeoplasms

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPhase 1 Clinical

Highest Status in ChinaN/A

Originator CompaniesBaxalta Incorporated Precision Biosciences Inc

China Registration ClassN/A

Develop Information

Active CompaniesPrecision Biosciences Inc

Inactive CompaniesN/A

Active IndicationsHematologic Neoplasms

Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A